{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:53:01Z","timestamp":1787507581888,"version":"build-2736575974"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>\n                    About 71% of healthcare-associated infections are due to antibiotic-resistant bacteria, such as carbapenem-resistant\n                    <jats:italic>A. baumannii<\/jats:italic>\n                    , classified by World Health Organization into a critical priority group of pathogens. The antimicrobial resistance profile of\n                    <jats:italic>A. baumannii<\/jats:italic>\n                    relies on its ability to produce several virulence factors, including biofilm formation. Its ability to adhere and persist on surfaces as biofilm has contributed to its pathogenicity and drug resistance. In this study, the ability of an antimicrobial peptide (a chionodracine-derived peptide named KHS-Cnd) to inhibit or reduce biofilm formation was investigated as an example of a potential strategy to counteract infections caused by biofilm-forming pathogens. To this aim, the antimicrobial profiles were first analyzed in selected\n                    <jats:italic>A. baumannii<\/jats:italic>\n                    strains, two reference and six clinical strains, all biofilm-forming with different capability, regardless of whether they are drug resistant or sensitive. Successively, we investigated the bactericidal activity of the peptide that showed MIC values ranging from 5 to 10 \u00b5M and a significative antibiofilm activity on all tested strains at sub-inhibitory concentrations. In fact, KHS-Cnd can hinder biofilm\n                    <jats:italic>A. baumannii<\/jats:italic>\n                    strains formation with an inhibition percentage ranging between 65% and 10%. Also a statistically significant reduction of mature biofilm ranging from 20% to 50% was observed in four out of eight tested\n                    <jats:italic>A. baumannii<\/jats:italic>\n                    strains. KHS-Cnd impacts various stages of biofilm formation, including the inhibition of surface-associated and twitching motilities depending on the different strain. In particular, our results showed that only two strains possessed surface-associated motility that was strongly impaired by KHS-Cnd treatment; three clinical strains, instead, showed twitching motility, whose inhibition for two of them was evident after 24 h of incubation with peptide. Moreover, the invasion of pulmonary cells by\n                    <jats:italic>A. baumannii<\/jats:italic>\n                    was significantly impaired with a reduction of about 32% after treatment with 1.25 \u00b5M KHS-Cnd. Finally, when the peptide was used together with ceftazidime\/avibactam against resistant\n                    <jats:italic>A. baumannii<\/jats:italic>\n                    strains, it was able to reduce the minimal inhibitory concentration of antibiotics needed to inhibit the microorganism growth.\n                  <\/jats:p>","DOI":"10.3389\/fcimb.2025.1526246","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T01:59:52Z","timestamp":1739498392000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["A chionodracine-derived peptide, KHS-Cnd, as an anti-virulence agent against multidrug-resistant Acinetobacter baumannii clinical strains"],"prefix":"10.3389","volume":"15","author":[{"given":"Marco","family":"Artini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Imperlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Buonocore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Vrenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Selan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s42522-024-00115-7","article-title":"Combating antibiotic resistance in a one health context: a plethora of frontiers","volume":"6","author":"Ajose","year":"2024","journal-title":"One Health Outlook."},{"key":"B2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41522-024-00560-2","article-title":"Microbiome-derived antimicrobial peptides show therapeutic activity against the critically important priority pathogen, Acinetobacter baumannii","volume":"10","author":"Alexander","year":"2024","journal-title":"NPJ Biofilms Microbiomes."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113494","article-title":"Anti-Virulence Potential of a Chionodracine-Derived Peptide against Multidrug-Resistant Pseudomonas aeruginosa Clinical Isolates from Cystic Fibrosis Patients","volume":"23","author":"Artini","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12101556","article-title":"Antarctic marine bacteria as a source of anti-biofilm molecules to combat ESKAPE pathogens","volume":"12","author":"Artini","year":"2023","journal-title":"Antibiot. (Basel)."},{"key":"B5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.dci.2019.02.012","article-title":"Fish-derived antimicrobial peptides: Activity of a chionodracine mutant against bacterial models and human bacterial pathogens","volume":"96","author":"Buonocore","year":"2019","journal-title":"Dev. Comp. Immunol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmicr.2022.100175","article-title":"Biofilm-forming microorganisms causing hospital-acquired infections from intravenous catheter: A systematic review","volume":"3","author":"Cangui-Panchi","year":"2022","journal-title":"Curr. Res. Microb. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0176790","DOI":"10.1371\/journal.pone.0176790","article-title":"Acinetobacter baumannii strains isolated from patients in intensive care units in Goi\u00e2nia, Brazil: Molecular and drug susceptibility profiles","volume":"12","author":"Castilho","year":"2017","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00284-022-03071-5","article-title":"Acinetobacter baumannii Biofilm Formation: Association with Antimicrobial Resistance and Prolonged Survival under Desiccation","volume":"79","author":"Choudhary","year":"2022","journal-title":"Curr. Microbiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1080\/21505594.2021.1950268","article-title":"Importance of twitching and surface-associated motility in the virulence of Acinetobacter baumannii","volume":"12","author":"Corral","year":"2021","journal-title":"Virulence"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2016.00163","article-title":"Acinetobacter baumannii isolated from lebanese patients: phenotypes and genotypes of resistance, clonality, and determinants of pathogenicity","volume":"6","author":"Dahdouh","year":"2016","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4014\/jmb.2405.0501","article-title":"Evaluating the antimicrobial efficacy of a designed synthetic peptide against pathogenic bacteria","volume":"34","author":"de Moura Cavalheiro","year":"2024","journal-title":"J. Microbiol. Biotechnol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijheh.2022.114006","article-title":"Prevalence of ESKAPE pathogens in the environment: Antibiotic resistance status, community-acquired infection and risk to human health","volume":"244","author":"Denissen","year":"2022","journal-title":"Int. J. Hyg. Environ. Health"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1099\/jmm.0.001028","article-title":"Sub-MIC effects of a proline-rich antibacterial peptide on clinical isolates of Acinetobacter baumannii","volume":"68","author":"Dolzani","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-1020","article-title":"Comparative analysis of surface-exposed virulence factors of Acinetobacter baumannii","volume":"15","author":"Eijkelkamp","year":"2014","journal-title":"BMC Genomics"},{"key":"B15","volume-title":"Survey protocol for the ECDC genomic based survey of carbapenem-resistant","year":"2024"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.2147\/IDR.S169894","article-title":"Acinetobacter baumannii biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments","volume":"11","author":"Eze","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"B17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s12602-023-10070-w","article-title":"Antibacterial properties and efficacy of LL-37 fragment GF-17D3 and scolopendin A2 peptides against resistant clinical strains of staphylococcus aureus, pseudomonas aeruginosa, and acinetobacter baumannii in vitro and in vivo model studies","volume":"16","author":"Farzi","year":"2024","journal-title":"Probiot. Antimicrob. Proteins."},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-99-8799-3_10","article-title":"Acinetobacter baumannii virulence factors and biofilm components: synthesis, structure, function, and inhibitors","volume-title":"ESKAPE Pathogens","author":"Ganesh","year":"2024"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0287211","DOI":"10.1371\/journal.pone.0287211","article-title":"Prevalence of biofilm producing Acinetobacter baumannii clinical isolates: A systematic review and meta-analysis","volume":"18","author":"Gedefie","year":"2023","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00203-024-04133-x","article-title":"Antimicrobial peptide-based strategies to overcome antimicrobial resistance","volume":"206","author":"Girdhar","year":"2024","journal-title":"Arch. Microbiol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109942","article-title":"Acinetobacter baumannii biofilm was inhibited by tryptanthrin through disrupting its different stages and genes expression","volume":"27","author":"Guo","year":"2024","journal-title":"iScience"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106866","article-title":"Characterisation of carbapenemase-producing Acinetobacter baumannii isolates from Danish patients 2014-2021: detection of a new international clone-IC11","volume":"62","author":"Hansen","year":"2023","journal-title":"Int. J. Antimicrob. Agents."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010072","article-title":"Antimicrobial proteins: structure, molecular action, and therapeutic potential","volume":"15","author":"Hassan","year":"2022","journal-title":"Pharmaceutics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12010184","article-title":"Antimicrobial peptides against bacterial pathogens: innovative delivery nanosystems for pharmaceutical applications","volume":"12","author":"Imperlini","year":"2023","journal-title":"Antibiot. (Basel)."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2024.171311","article-title":"Membrane alteration, anti-virulence properties and metabolomic perturbation of a chionodracine-derived antimicrobial peptide, KHS-Cnd, on two bacteria models","volume":"182","author":"Imperlini","year":"2024","journal-title":"Peptides"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-023-12975-6","article-title":"Motility of Acinetobacter baumannii: regulatory systems and controlling strategies","volume":"108","author":"Jeong","year":"2024","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"100940","DOI":"10.1016\/j.lanmic.2024.07.003","article-title":"WHO publishes updated list of bacterial priority pathogens","volume":"5","author":"Jesudason","year":"2024","journal-title":"Lancet Microbe"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.134568","article-title":"The role of AbaI quorum sensing molecule synthase in host cell inflammation induced by Acinetobacter baumannii and its effect on zebrafish infection model","volume":"278","author":"Jiang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137036","article-title":"Investigating the Effectiveness of Ceragenins against Acinetobacter baumannii to Develop New Antimicrobial and Anti-Adhesive Strategies","volume":"25","author":"Karasi\u0144ski","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.01532","article-title":"Antimicrobial peptide Cec4 eradicates the bacteria of clinical carbapenem-resistant Acinetobacter baumannii biofilm","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Microbiol."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106363","article-title":"Advancements, challenges and future perspectives on peptide-based drugs: Focus on antimicrobial peptides","volume":"181","author":"Luo","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25136814","article-title":"Unveiling the secrets of acinetobacter baumannii: resistance, current treatments, and future innovations","volume":"25","author":"Marino","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2021.126722","article-title":"An overview of Acinetobacter baumannii pathogenesis: Motility, adherence and biofilm formation","volume":"247","author":"Mea","year":"2021","journal-title":"Microbiol. Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s10096-023-04677-8","article-title":"Co-regulation of biofilm formation and antimicrobial resistance in Acinetobacter baumannii: from mechanisms to therapeutic strategies","volume":"42","author":"Mendes","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10020127","article-title":"Acinetobacter baumannii: its clinical significance in human and veterinary medicine","volume":"10","author":"Nocera","year":"2021","journal-title":"Pathogens"},{"key":"B36","doi-asserted-by":"publisher","first-page":"41331","DOI":"10.1039\/c8ra08065h","article-title":"Design and characterization of chionodracine-derived antimicrobial peptides with enhanced activity against drug-resistant human pathogens","volume":"8","author":"Olivieri","year":"2018","journal-title":"RSC. Adv."},{"key":"B37","doi-asserted-by":"publisher","first-page":"5558","DOI":"10.1073\/pnas.1800961115","article-title":"Structural basis for Acinetobacter baumannii biofilm formation","volume":"115","author":"Pakharukova","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106205","article-title":"Bactericidal activities and action mechanism of the novel antimicrobial peptide Hylin a1 and its analog peptides against Acinetobacter baumannii infection","volume":"175","author":"Park","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12030410","article-title":"Dissemination of Clinical Acinetobacter baumannii Isolate to Hospital Environment during the COVID-19 Pandemic","volume":"12","author":"Pustijanac","year":"2023","journal-title":"Pathogens"},{"key":"B40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-981-15-1695-5_14","article-title":"Acinetobacter baumannii: infections and drug resistance","volume-title":"Model organisms for Microbial Pathogenesis, Biofilm Formation and Antimicrobial Drug Discovery","author":"Rajkumari","year":"2020"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11020234","article-title":"The antimicrobial peptide esc(1-21) synergizes with colistin in inhibiting the growth and in killing multidrug resistant acinetobacter baumannii strains","volume":"11","author":"Sacco","year":"2022","journal-title":"Antibiot. (Basel)."},{"key":"B42","volume-title":"WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance","author":"Sati","year":"2024"},{"key":"B43","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.bbrc.2019.08.062","article-title":"Cationic antimicrobial peptide and its poly-N-substituted glycine congener: Antibacterial and antibiofilm potential against A. baumannii","volume":"518","author":"Sharma","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10050593","article-title":"Bacterial resistance to antimicrobial agents","volume":"10","author":"Varela","year":"2021","journal-title":"Antibiot. (Basel)."},{"key":"B45","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/ja.2015.30","article-title":"Investigation of the molecular epidemiology of Acinetobacter baumannii isolated from patients and environmental contamination","volume":"68","author":"Ying","year":"2015","journal-title":"J. Antibiot. (Tokyo)."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.134670","article-title":"Synergism of colistin and globular endolysins against multidrug-resistant gram-negative bacteria","volume":"278","author":"Zhang","year":"2024","journal-title":"Int. J. Biol. Macromol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1526246\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T01:59:56Z","timestamp":1739498396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1526246\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":46,"alternative-id":["10.3389\/fcimb.2025.1526246"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1526246","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"article-number":"1526246"}}